These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001. Collins SE; Jean Juste MA; Koenig SP; Secours R; Ocheretina O; Bernard D; Riviere C; Calnan M; Dunning A; Hurtado Rúa SM; Johnson WD; Pape JW; Fitzgerald DW; Severe P Int J Tuberc Lung Dis; 2015 Jan; 19(1):50-7. PubMed ID: 25519790 [TBL] [Abstract][Full Text] [Related]
4. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D; AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817 [TBL] [Abstract][Full Text] [Related]
5. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Chang LW; Harris J; Humphreys E Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969 [TBL] [Abstract][Full Text] [Related]
6. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. Sterling TR; Chaisson RE; Keruly J; Moore RD J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536 [TBL] [Abstract][Full Text] [Related]
7. Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children. Ásbjörnsdóttir KH; Hughes JP; Wamalwa D; Langat A; Slyker JA; Okinyi HM; Overbaugh J; Benki-Nugent S; Tapia K; Maleche-Obimbo E; Rowhani-Rahbar A; John-Stewart G AIDS; 2016 Nov; 30(18):2835-2843. PubMed ID: 27603293 [TBL] [Abstract][Full Text] [Related]
8. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. Kuznik A; Iliyasu G; Habib AG; Musa BM; Kambugu A; Lamorde M AIDS; 2016 Nov; 30(18):2865-2873. PubMed ID: 27662547 [TBL] [Abstract][Full Text] [Related]
9. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. HIV Paediatric Prognostic Markers Collaborative Study Lancet; 2005 Nov; 366(9500):1868-74. PubMed ID: 16310553 [TBL] [Abstract][Full Text] [Related]
10. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. Sabin CA; Cooper DA; Collins S; Schechter M AIDS; 2013 Jul; 27(12):1839-46. PubMed ID: 24179998 [TBL] [Abstract][Full Text] [Related]
11. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D; AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492 [TBL] [Abstract][Full Text] [Related]
12. Predictors of response to highly active antiretroviral therapy. Low A; Markowitz M AIDS Read; 2006 Aug; 16(8):425-8, 430-1, 434, 436. PubMed ID: 16933376 [TBL] [Abstract][Full Text] [Related]
13. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi. Gitura B; Joshi MD; Lule GN; Anzala O East Afr Med J; 2007 Oct; 84(10):466-72. PubMed ID: 18232267 [TBL] [Abstract][Full Text] [Related]
14. Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Bigna JJ; Plottel CS; Koulla-Shiro S Infect Dis Poverty; 2016 Sep; 5(1):85. PubMed ID: 27593965 [TBL] [Abstract][Full Text] [Related]
15. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience. Erhabor O; Ejele OA; Nwauche CA Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344 [TBL] [Abstract][Full Text] [Related]
16. An update and review of antiretroviral therapy. Piacenti FJ Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488 [TBL] [Abstract][Full Text] [Related]
17. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD; Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022 [TBL] [Abstract][Full Text] [Related]
18. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L; AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104 [TBL] [Abstract][Full Text] [Related]
19. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD; Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]